Biotechnology

Tuesday Nov 10, 2020 - 11:12 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters LOI with Asymchem for MS1819 Development, Production

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced its entry into a binding letter of intent (“LOI”) with Asymchem, a leading global contract development and manufacturing service (“CDMO”) provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency. Under the agreement, Asymchem will implement fermentation, verify protein expression and ultimately…

Tuesday Nov 10, 2020 - 10:41 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Selected to Present at Upcoming Investor Conferences

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is slated to present at two upcoming investor conferences. Representing LexaGene at the conferences will be founder and CEO Jack Regan. Regan will be a presenter at the Investor Summit Group Conference held Nov. 18, 2020, at 1:30 p.m. and at the Canaccord Genuity 2020 Medical Technologies &…

Monday Nov 09, 2020 - 9:45 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update at 4:30 p.m. ET on Nov. 12, 2020, to discuss the clinical trial design for its upcoming Phase 2 U.S. trial for Berubicin. CNSP’s lead drug candidate – Berubicin –…

Friday Nov 06, 2020 - 9:17 am

InvestorNewsBreaks – Turning Point Therapeutics Inc. (NASDAQ: TPTX) Secures $460M in Underwritten Public Offering

Turning Point Therapeutics (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, has closed an underwritten public offering of 5,287,357 shares of its common stock, including 689,655 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Turning Point Therapeutics secured approximately $460 million in gross proceeds, with each of the…

Thursday Nov 05, 2020 - 12:30 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with a high unmet medical need, today announced the appointment of Dr. Khalid Islam to its board of directors. Dr. Islam was the chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led its transition to a profitable company that subsequently sold for…

Thursday Nov 05, 2020 - 11:55 am

InvestorNewsBreaks – Applied UV Inc. (NASDAQ: AUVI) Enters Non-Binding LOI to Acquire Airocide(TM) System for Airborne Pathogen Reduction

Applied UV (NASDAQ: AUVI), an infection prevention technology company that applies the power of ultra violet C ("UV-C") light utilizing its patented devices to destroy pathogens, today announced its entry into a non-binding letter of intent ("LOI") with Akida Holdings LLC. In addition to its exclusive joint distribution and licensing agreement with Akida Holdings, the LOI is to explore the possibility of acquiring certain key…

Wednesday Nov 04, 2020 - 12:37 pm

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Report Q3 2020 Financial Results, Host Conference Call

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced that it will release financial results for its second quarter ended September 30, 2020, on Thursday, Nov. 12, 2020, as well as host a conference call at 9:00 a.m. Eastern Time. According to the update, Erez Raphael, chief executive officer, Rick Anderson, president and general manager of North America and Zvi Ben-David,…

Wednesday Nov 04, 2020 - 9:36 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, was featured in an institutional research report by Craig-Hallum Capital Group LLC. The report discusses Craig-Hallum’s research coverage of PCSA and details the company’s experienced management team and its ownership rights to five programs that are de-risked by existing data.…

Tuesday Nov 03, 2020 - 2:58 pm

InvestorNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Stock2Me Podcast

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. The episode features Shawn K. Singh, CEO of VistaGen, as he discusses the company’s innovative development pipeline and focus on bringing new,…

Tuesday Nov 03, 2020 - 1:02 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Call, Live Webcast to Discuss Q3 2020 Results, Clinical Pipeline

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, today announced that it will host a conference call and live webcast at 5:30 p.m. Eastern Time on Nov. 12, 2020. Topics will include review of the company’s third quarter 2020 results and an update on its clinical pipeline, including…

Tuesday Nov 03, 2020 - 12:00 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Appoints Experienced Innovator as VP of Strategy

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced the appointment of a new vice president of strategy and business development. In her new role, Amy Griffith will be responsible for the company’s development of strategic and tactical initiatives, as well as new sales strategies. A veteran sales and innovation expert, Griffith has held executive management positions at leading technology companies and…

Friday Oct 30, 2020 - 12:23 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Launch of New Branding for Upcoming Combination Clinical Trials

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead drug candidate, REQORSA(TM) (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso(R) (osimertinib), which received U.S. Food and Drug Administration (“FDA”) Fast Track Designation earlier this year, as well as the combination of REQORSA…

Tuesday Oct 27, 2020 - 1:52 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Positive Results in Ongoing Phase 2 Combination Therapy Trial with MS1819

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, recently announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption (“CFA”)…

Tuesday Oct 27, 2020 - 11:49 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Announces Partnership with Dalmore Group for Upcoming Offering

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is partnering with the Dalmore Group, a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”), for a regulation A+ offering. Based in New York, the Dalmore Group has an active presence in the Reg A+ equity funding space and is one of the most active broker-dealers in…

Monday Oct 19, 2020 - 12:25 pm

InvestorNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central…

Wednesday Oct 14, 2020 - 11:00 am

InvestorNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Presents New DetermaRx(TM) Prospective Data at IASLC 2020 Conference

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, is presenting new prospective data on DetermaRx(TM) at the IASLC 2020 North America Conference on Lung Cancer taking place on October 22. Gavitt Woodard, M.D., assistant professor, Yale School of Medicine, and lead author on the study is presenting the data…

InvestorNewsBreaks

NewsBreak Category: Biotechnology